Host Kathrin Berg leads a conversation with local children pediatric geneticist and counselor. In this episode of the El Paso Physician, our host Kathrin Berg leads a conversation with local children ... Seeking Alpha: Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5) Pediatric participants demonstrated large gains in cone-mediated vision; therapy remains well tolerated with no ocular serious adverse events or dose-limiting toxicities Lasting, durable responses ...
Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5) Nasdaq: Opus Genetics Doses First Pediatric Patient in Phase 1/2 Trial of OPGx-LCA5, Anticipates Initial Data by Q3 2025 Opus Genetics, Inc. announced the dosing of the first pediatric patient in its Phase 1/2 trial for OPGx-LCA5, a gene therapy targeting Leber congenital amaurosis (LCA). Initial results from this ... Opus Genetics Doses First Pediatric Patient in Phase 1/2 Trial of OPGx-LCA5, Anticipates Initial Data by Q3 2025 Seeking Alpha: Opus Genetics Announces One-Month Clinical Data from Pediatric Patient in Phase 1/2 Trial of OPGx-LCA5 Gene Therapy in Inherited Retinal Diseases
